ImmunoGen Stock – Fundamental Analysis
Not enough price data available yet.
Fundamental Data & Ratios (Balance sheet update: 3/9/2023)
| Balance Sheet | Total Assets | 348,936,000.00 | ROE | – |
| Balance Sheet | Total Equity | 155,826,000.00 | ROA | – |
| Cashflow | Capital Expenditures | -1,889,000.00 | P/FCF | – |
| Cashflow | Free Cash Flow | -231,166,000.00 | – | – |
| Cashflow | Operating Cash Flow | -197,889,000.00 | P/CF | – |
| Income | Earnings per Share (diluted) | -0.88 | Div. Yield | – |
| Income | Net Income | -73,522,000.00 | P/E | – |
| Income | Shares Outstanding | 226,046,000.00 | P/B | – |
| Income | Total Revenue | 287,614,000.00 | P/S | – |
Ratios calculated on: –
Company Description
ImmunoGen, Inc. (ImmunoGen) develops targeted, antibody-based therapeutics for the treatment of cancer. ImmunoGen designs linkers that enable antibody-based therapeutics for the treatment of cancer agents to remain stably attached to the antibodies while in the blood stream and be released in their fully active form after delivery to a cancer cell. An anticancer compound made using the Company´s Targeted Antibody Payload (TAP), technology consists of a monoclonal antibody. The Company´s TAP technology is designed to enable the creation of well-tolerated anticancer products. As of June 30, 2012, ImmunoGen had three wholly owned clinical-stage product candidates included IMGN901, IMGN853, and IMGN529, and other TAP compounds in earlier stages of development.
Additional comparison and history views are available after login.
Finanzoo GmbH assumes no liability for the accuracy of the information provided! All information is provided without guarantee. Sources: www.bundesanzeiger.de, www.sec.gov, www.immunogen.com
All metrics and scores are an automated evaluation and not investment advice or a recommendation to buy or sell. Finanzoo GmbH or its shareholders may themselves hold positions in the securities shown.
Learn more